Resources
60 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 5/14/2024 (updated 5/24/2024)
These webinars are an opportunity for grantees to come together to learn and share knowledge on how best to identify, organize, compile, and visualize your data and information in a variety of formats for different audiences to help demonstrate the impact of your grant.
Posted 4/15/2024 (updated 5/23/2024)
The 2024 RCORP Data Coordinator meeting series began in May 2024, hosted by RCORP-Evaluation (Customer Value Partners), in partnership with RCORP-TA (JBS International). The purpose of this meeting series is to present a deep dive into all aspects of PIMS data collection with an overview of data requirements, data collection, and addressing common data collection challenges with hands-on best practices. This series is geared towards Data Coordinators; however, anyone involved in RCORP grant data collection is welcome to join. You can find slides, recordings, and materials from the meetings linked below.
Posted 4/5/2024
The Providers Clinical Support System - Medications for Alcohol Use Disorder (PCSS-MAUD) is a national project funded by the Substance Abuse and Mental Health Services Administration to provide free, comprehensive training, guidance, and mentoring on the prevention, diagnosis, and treatment of alcohol use disorder.
Posted 3/29/2024
A planning committee of the National Academies of Sciences, Engineering, and Medicine organized and conducted a two-day virtual public workshop that brought together data experts, program implementers and evaluators, and other key interested parties to explore data collection efforts, evidence gaps, and research needs on harm reduction for people who use drugs (PWUD).
Posted 3/15/2024 (updated 3/28/2024)
Clinical experts from the Providers Clinical Support System (PCSS) created the Substance Use Disorder 101 Core Curriculum for Healthcare Professionals. With the addition of two new module topics, the 23 modules in this 2023 curriculum provide an overview of evidence-based practices in the prevention, identification, and treatment of substance use disorders and co-occurring medical and psychiatric conditions for a variety of populations.
Posted 3/10/2024 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration's (SAMHSA) updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. It emphasizes harm reduction and access to treatment as essential aspects of overdose prevention.
Posted 1/8/2024 (updated 3/28/2024)
The Neonatal Abstinence Syndrome (NAS) Cohort I tip sheet is a result of collaborative efforts of the NAS Cohort I grant recipients. Drawing on the insights and experiences of our grantees, we identified 9 key recommendations. These tips serve not only as a guiding framework for future NAS cohort grantees but also offers valuable guidance to all RCORP grant cohorts. This resource aims to enhance effectiveness and increase the impact of all RCORP grantee initiatives.
Posted 9/8/2023 (updated 3/26/2024)
September 2023 is National Recovery Month and HRSA’s Office of Women’s Health has a toolkit to support organizations and health care providers that care for women living with opioid use disorder (OUD). The toolkit provides strategies to engage women with OUD, care coordination for support, and other resources.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of RCORP’s ability to impact service capacity, access, and health status within our rural communities.
Posted 5/26/2023 (updated 3/27/2024)
Providers Clinical Support System (PCSS), a Substance Abuse and Mental Health Services Administration-funded grant initiative, announced the release of Practice-Based Guidelines: Buprenorphine in the Age of Fentanyl. The guide gives practitioners a blueprint on treating fentanyl use disorder based on available research combined with emerging clinical experience on the use of buprenorphine in the treatment of individuals using fentanyl and other highly potent synthetic opioids.